<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9929">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01903005</url>
  </required_header>
  <id_info>
    <org_study_id>OX219-008</org_study_id>
    <nct_id>NCT01903005</nct_id>
  </id_info>
  <brief_title>Follow up Study to Assess Safety, Treatment Efficacy and Adherence of OX219 (Buprenorphine/Naloxone).</brief_title>
  <official_title>A Multi-center, Open-label, 24-week, Follow-up Study to Assess Safety, Efficacy and Treatment Adherence for Maintenance Treatment of Opioid Dependence With OX219</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orexo AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orexo AB</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess treatment efficacy and adherence of OX219
      (Buprenorphine/Naloxone).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-center-, open-label-, uncontrolled-, single armed-, 24-week, follow-up study to
      assess safety, efficacy and treatment adherence for maintenance treatment of opioid
      dependence with OX219.

      Only patients from studies; OX219-006 or OX219-007 is permitted to participate

      Total study treatment 24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To assess the safety and tolerability  of OX219(AE)</measure>
    <time_frame>Participants will be followed for the duration of an expected average of 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Reported Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the safety and tolerability of OX219 (Vital Signs)</measure>
    <time_frame>Participants will be followed for the duration of an expected average of 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Blood pressure and pulse rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the safety and tolerability of OX219 (Safety laboratory tests)</measure>
    <time_frame>Participants will be followed for the duration of an expected average of 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Urine and blood samples (clinical chemistry and hematology)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the safety and tolerability of OX219 (C-SSRS)</measure>
    <time_frame>Participants will be followed for the duration of an expected average of 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assess suicidal ideation/behavior with Columbia Suicidal Severity Rating Scale (C-SSRS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the safety and tolerability of OX219 (Local tolerability assessments)</measure>
    <time_frame>Participants will be followed for the duration of an expected average of 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Visual examine of the mouth to check for any local irritation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Opiate Withdrawal Scale score (COWS)</measure>
    <time_frame>Participants will be followed for the duration of an expected average of 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Scale for assessment of opioid withdrawal symptoms by clinician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Opiate Withdrawal Scale score (SOWS)</measure>
    <time_frame>Participants will be followed for the duration of an expected average of 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Scale for assessment of opioid withdrawal symptoms by subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Craving VAS</measure>
    <time_frame>Participants will be followed for the duration of an expected average of 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Scale for assessment of treatment effects of opioid cravings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine drug screen (UDS) and/or urine dipstick</measure>
    <time_frame>Participants will be followed for the duration of an expected average of 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Screen for illicit drugs/opioids/buprenorphine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self report of substance use/opioid use</measure>
    <time_frame>Participants will be followed for the duration of an expected average of 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient assessment of treatment effects on illicit drug use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Addiction Severity Index - Lite (ASI-Lite)</measure>
    <time_frame>Participants will be followed for the duration of an expected average of 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess treatment effects on addiction severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement (PGI-I)</measure>
    <time_frame>Participants will be followed for the duration of an expected average of 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient assessment of improvement/deterioration of opioid dependence severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Severity (CGI-S)</measure>
    <time_frame>Participants will be followed for the duration of an expected average of 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinician assessment of opioid dependence severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Improvement (CGI-I)</measure>
    <time_frame>Participants will be followed for the duration of an expected average of 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinician assessment of improvement/deterioration of opioid dependence severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate retention in treatment during study period</measure>
    <time_frame>Participants will be followed for the duration of an expected average of 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Recording of dose administrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Numerical rating scale (NRS)</measure>
    <time_frame>Participants will be followed for the duration of an expected average of 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessment of concomitant pain scale (numerical rating scale [NRS])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Constipation Symptoms (PAC-SYM)</measure>
    <time_frame>Participants will be followed for the duration of an expected average of 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess the patient perspective on constipation symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 ratings</measure>
    <time_frame>Participants will be followed for the duration of an expected average of 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient general quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work productivity/activity impairment: Specific health problem questionnaire (WPAI:SHP)</measure>
    <time_frame>Participants will be followed for the duration of an expected average of 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient questionnaire to evaluate the influence of opioid dependence on work capacity / other activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess treatment compliance</measure>
    <time_frame>Participants will be followed for the duration of an expected average of 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient reported intake confirmed by drug accountability.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Opioid Dependence, on Agonist Therapy</condition>
  <arm_group>
    <arm_group_label>OX219</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Week 1-24 OX219 buprenorphine/naloxone sublingual tablet (open-label)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>buprenorphine/naloxone</intervention_name>
    <description>OX219 buprenorphine/naloxone sublingual tablets</description>
    <arm_group_label>OX219</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Signed informed consent form (ICF).

          2. Patient has completed the OX219-006 or the OX219-007 study.

          3. Female subjects of child bearing potential who use a reliable method of contraception
             (e.g. hormonal, condom with spermicide, IUD) during the previous OX219-006 or
             OX219-007 studies and during the duration of the OX219-008 study. Females of nonchild
             bearing potential who are either surgically sterile (hysterectomy, bilateral
             oophorectomy, bilateral salpingectomy, tubal ligation), or post-menopausal as defined
             by being at least 50 years of age and having had an absence of menses for at least 2
             years are also allowed.

        Exclusion criteria

          1. Females who are pregnant (positive pregnancy test) or lactating, or planning to be
             pregnant during study.

          2. Participants who are unwilling or unable to comply with the requirements of the
             protocol (e.g., pending incarceration) or are in a situation or condition that, in
             the opinion of the investigator, may interfere with participation in the study.

          3. Participants who are participating in any other clinical study in which medication(s)
             are being delivered.

          4. Participants with any known allergy or sensitivity or intolerance to BUP, NAL or any
             related drug, or history of any drug hypersensitivity or intolerance which in the
             opinion of the investigator, would compromise the safety of the subject or the study.

          5. Participations with a contra-indicated serious medical condition.

          6. Participants who are at suicidal risk as determined by meeting any of the following:
             history of suicidal ideation â‰¤ 3 months prior to baseline with a score of 4 (intent
             to act) or 5 (specify plan and intent) on the C-SSRS; history of suicidal behavior
             (actual attempt, interrupted attempt, aborted attempt, and/or preparatory
             acts/behavior) on the C-SSRS.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kent Hoffman</last_name>
    <role>Principal Investigator</role>
    <affiliation>TRY Research, 406 Lake Howell Road, Maitland, Florida 32751</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Jefferson County</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston, Marion</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maricopa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles County</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego County</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Broward County</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia County</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duval County</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greater Metro Orlando area</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville Metropolitan area</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami-Dade County</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osceola County</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Beach County</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>DeKalb County</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicagoland</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore county</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol County</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rankin</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis Metro Area</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warren County</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma County</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland metropolitan area</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delaware County</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia County</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston County</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake County</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Benton County</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>July 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid, Dependence, agonist, Buprenorphine, Naloxone</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
